Back to products
Beacon Pharmaceuticals Ltd.
- All products
- Hepatitis B Virus28 products
Bladder Cancer39 products
Breast Cancer38 products
- Colorectal Cancer28 products
Diabetic25 products
- Endometrial Cancer29 products
- Hepatitis C Virus21 products
- Leukaemia3 products
- ONCOLOGY PRODUCTS29 products
- Rectal Cancer16 products
- Solid Tumor6 products
- Taskin50 products
- Anti-Diabetic6 products
- BEST SELLER16 products
- Bladder Cancer19 products
- Breast Cancer19 products
- Colon & Rectal Cancer12 products
- Colorectal Cancer10 products
- Diabetic12 products
- Endometrial Cancer13 products
- Hepatitis B Virus7 products
- Hepatitis C Virus9 products
- Ibrutinib4 products
- Kidney Cancer22 products
- Leukaemia12 products
- Liver Cancer22 products
- Lung Cancer24 products
- Lymphoma13 products
- Mantle Cell Lymphoma11 products
- Melanoma12 products
- Non-Hodgkin7 products
- ONCOLOGY18 products
- ONCOLOGY PRODUCTS41 products
- Tumor2 products
AFANIX 40 MG
DESCRIPTION Afatinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)
AXINIX 1 MG
DESCRIPTION Axinix (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one
AXINIX 5 MG
DESCRIPTION Axinix (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one
CRIZOCENT 250 MG
Presentation Crizocent 250: Each capsule contains Crizotinib INN 250 mg Description Crizotinib is an inhibitor of receptor tyrosine kinases including
CRIZONIX 250 MG
Crizonix Capsule 250 mg Indications Crizotinib is a kinase inhibitor indicated for the treatment of patients with- Metastatic non-small cell lung
HERNIX 40 MG
Hernix Tablet Neratinib 40 mg Beacon Pharmaceuticals Ltd. Indications Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of
LAPANIX 250 MG
LAPANIX 250 MG Lapatinib Beacon Pharmaceuticals Ltd. Product Description: Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase
LENVANIX 10 MG
Lenvanix (lenvatinib) 10 Mg Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor
LENVANIX 4 MG
Lenvanix (lenvatinib) 4 Mg Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor
OBETIX 5 MG
DESCRIPTION Product Description: Obetix is the only choice for Primary Biliary Cirrhosis (PBC) with the combination of UDCA (Ursodeoxycholic Acid)
PALBONIX 125 MG
DESCRIPTION Product Description: Palbociclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
REGONIX 40 MG
Product Description: Regorafenib is an oral multi-kinase inhibitor involved in normal cellular functioning and in pathological processes such as oncogenesis,
